On March 29th 2023, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Xavier Barril, Ph.D. (Gain Therapeutics’ CTO), Brandon …
Events and Team Interviews
On April 12, 2023, Gain Therapeutics announced Evan Ballantyne as the company’s new Chief Financial Officer. Ballantyne has been around the block. His humble demeanor …
Download : AD PD Infographic
On Wednesday, March 29th, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Gain Therapeutics’ CTO Xavier Barril, Ph.D. and …
Virtual Fireside Chat: Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts on Wednesday, March 29th at 12:00 p.m. EDT Listen …
You joined Gain Therapeutics in 2020 when it was a private company and played a role in helping to take the company public. What was …
Listen to Podcast Watch the full presentation video of Computational Drug Discovery With Gain Therapeutics Matthias Alder In conversation with Mathias Alder, CEO of …
What scientific innovation are you most excited about? Which innovation do you think will have the most impact in the next 20 years? I don’t …
Your educational background is in law. What was the trajectory of your career? Well, it was an evolution. Throughout my career, I’ve always been involved …
Watch the full presentation video of Jeff Harman with Eric Richman, CEO of Gain Therapeutics: 00:01 I am Jeff Harmon 00:14 Eric Richman …
Watch the full presentation video below : 0:00 Jefferies HealthCare Conference 0:24 Forward Looking Statement 0:40 Investment Highlights 02:49 Gain Therapeutics Two-Pronged Approach …
Piper Sandler recently published a comprehensive report entitled “Deciphering the Artificial Intelligence / Machine Learning Matrix Code in Biotech.” Why is this report significant? Technology …
The Emerging Life Sciences Summit hosted by Oppenheimer will be on July 20th, 2022 in Montauk, NY. This yearly conference brings together the who’s who …
Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story. You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/ …
We sat down and got a chance to speak with the General Manager and President of Gain Therapeutics, Dr. Manolo Bellotto. You can follow him …
Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent …
1. What initially sparked your interest in neuroscience? Science has always interested me. Even as a young child I wanted to be a scientist or …
How do allosteric drugs compare to more traditional orthosteric drugs? Orthosteric drugs are compounds that bind to the active site of an enzyme. In order …
Presenting at Gain Therapeutics R&D Day, Manolo Bellotto, Ph. D elaborated on the Broad Application of Gain Therapeutics’ Structurally Targeted Allosteric Regulators (STARs). See the …
Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology. …
Manolo Bellotto, Ph. D gave an overview of Gain Therapeutics GBA program during Gain Therapeutics R&D Day. He explained how GBA program targets beta-glucocerebrosidase, or …
During Gain Therapeutics R&D Day, Samuel Broder, MD shares his perspective on Neuroscience and Beyond. The title of his presentation was “The Role of Allosteric …
Q: Dr. Xavier Barril, what was the evolution of your career? A: I received my PhD in Biochemistry from the University of Barcelona in 2001 …
Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for …
What is DeepMind? Deepmind AlphaFold protein folding structure prediction: DeepMind is a company that combines a variety of disciplines to develop artificial intelligence (AI) technology …
Genetic mutations are one of the most common causes of serious diseases. When genes are mutated it can affect the function of proteins which oftentimes …
Designing therapeutics that target cellular proteins can be difficult due to the lack of specific binding sites or the potential for disrupting the normal protein …
On September 30th, 2021 Gain Therapeutics presented at the Cantor Fitzgerald virtual global healthcare conference. Eric Richman, CEO and Manolo Bellotto, GM and President, sat …
MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar? This year due to the impact of the …